TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12206475

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg twice daily)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 9703041

Group type: EXPERIMENTAL
Intervention: Bioptic amorphic lenses training for 3 months
Number of subjects: 15
Study: 7855683

Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcutaneous muscle stimulation (TMS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corset
Number of subjects: 0
Study: 2571469

Group type: EXPERIMENTAL
Intervention: Bethanechol, 10 mg subcutaneously
Number of subjects: 132

Group type: COMPARATOR
Intervention: Midazolam, 5 mg intramuscularly
Number of subjects: 132

Group type: COMPARATOR
Intervention: Bethanechol and midazolam in combination
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 132
Study: 773581

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (DPH) 25 mg every 4 hr for four doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (DPH) 50 mg every 4 hr for four doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30859862

Group type: EXPERIMENTAL
Intervention: HMB-FA (3 g/day; n=14)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: HMB-Ca (3 g/day; n=15)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (cornstarch, 3 g/day; n=15)
Number of subjects: 44
Study: 28727581

Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg
Number of subjects: 697

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 697
Study: 25542677

Group type: EXPERIMENTAL
Intervention: Emotionally charged auditory stimulation (happy sounds)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Emotionally charged auditory stimulation (sad sounds)
Number of subjects: 104

Group type: COMPARATOR
Intervention: No auditory stimulation (control)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Emotionally charged auditory stimulation (happy or sad sounds)
Number of subjects: 104
Study: 23417633

Group type: EXPERIMENTAL
Intervention: Nurse-facilitated cognitive group (NFCG) intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30
Study: 21332331

Group type: EXPERIMENTAL
Intervention: Silymarin 140 mg 3 times daily
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Vitamin E 400 IU/day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Silymarin 140 mg 3 times daily and Vitamin E 400 IU/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 17868415

Group type: EXPERIMENTAL
Intervention: Conventional laparoscopic needle-holder (Karl Storz, Tuttlingen, Germany)
Number of subjects: 20

Group type: COMPARATOR
Intervention: First-generation articulating laparoscopic needle-holder (Cambridge Endo, Framingham, MA, USA)
Number of subjects: 20
Study: 16047465

Group type: EXPERIMENTAL
Intervention: Colesevelam HCl 2.3 g/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Colesevelam HCl 3.8 g/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Colesevelam HCl 2.3 g/day and 3.8 g/day
Number of subjects: 24
Study: 12019592

Group type: EXPERIMENTAL
Intervention: Worksite exercise training guided by a physiotherapist (60-minute sessions once a week for 8 months)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control group (received a 30-minute feedback on physical capacity and individual exercise prescription and counseling)
Number of subjects: 260
Study: 10084421

Group type: EXPERIMENTAL
Intervention: Preventable ADRs
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Predictable ADRs
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Severity of ADRs
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Length of hospitalization
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Incidence of preventable ADRs
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Most predictable ADRs
Number of subjects: 370
Study: 10155357

Group type: EXPERIMENTAL
Intervention: Salbutamol, 200 micrograms with HFA134a
Number of subjects: 0

Group type: COMPARATOR
Intervention: CFC preparations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salbutamol and CFC preparations
Number of subjects: 0
Study: 2257871

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 8
Study: 549537

Group type: EXPERIMENTAL
Intervention: d‐propranolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: dl‐propranolol
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 28890081

Group type: EXPERIMENTAL
Intervention: Valvular surgery alone
Number of subjects: 1462

Group type: EXPERIMENTAL
Intervention: Concomitant valvular and coronary artery bypass grafting surgery
Number of subjects: 1462

Group type: EXPERIMENTAL
Intervention: Use of cardiopulmonary bypass
Number of subjects: 1462

Group type: EXPERIMENTAL
Intervention: Ventricular pacing
Number of subjects: 1462

Group type: EXPERIMENTAL
Intervention: Concomitant coronary artery bypass grafting and valvular surgery
Number of subjects: 1462

Group type: EXPERIMENTAL
Intervention: Occurrence of postoperative atrial fibrillation
Number of subjects: 1462
Study: 27049643

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (600 IU/day)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2000 IU/day)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (4000 IU/day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 25217122

Group type: EXPERIMENTAL
Intervention: Self-cross-linked hyaluronic acid (HA) hydrogel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Carboxymethylcellulose (CMC) viscous foam
Number of subjects: 30
Study: 24364108

Group type: EXPERIMENTAL
Intervention: Exercising larynx and genioglossus
Number of subjects: 54

Group type: COMPARATOR
Intervention: UPPP surgery (Control group 1)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No treatment (Control group 2)
Number of subjects: 54
Study: 19812500

Group type: EXPERIMENTAL
Intervention: Bone-conducted vibration (BCV)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Air-conducted sound (ACS)
Number of subjects: 27
Study: 18546441

Group type: EXPERIMENTAL
Intervention: S-ketamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16150370

Group type: EXPERIMENTAL
Intervention: Biofeedback assisted diaphragmatic breathing and systematic relaxation
Number of subjects: 192

Group type: COMPARATOR
Intervention: Propranolol 80 mg/day
Number of subjects: 192
Study: 12622760

Group type: EXPERIMENTAL
Intervention: 4.0 g/day mesalazine
Number of subjects: 206

Group type: COMPARATOR
Intervention: 2.4 g/day mesalazine
Number of subjects: 206
Study: 10676721

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.25 microg/d) plus calcium carbonate (500 mg/d of elemental calcium)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 9345358

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy + Wertheim‐Meigs + radiotherapy
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control (Wertheim‐Meigs + adjuvant radiotherapy)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control (unresectable bulky tumors)
Number of subjects: 205
Study: 8379564

Group type: EXPERIMENTAL
Intervention: Recovering alcoholics
Number of subjects: 220

Group type: COMPARATOR
Intervention: Nonalcoholics
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Comorbidity of alcoholism and major depression
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 220
Study: 2876700

Group type: EXPERIMENTAL
Intervention: Benztropine mesylate 2 mg b.i.d. (withdrawal)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 29731164

Group type: EXPERIMENTAL
Intervention: Wellness Education (WE)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control
Number of subjects: 126
Study: 27512927

Group type: EXPERIMENTAL
Intervention: Rifaximin 1200 mg daily for 6 months
Number of subjects: 262

Group type: COMPARATOR
Intervention: Norfloxacin 400 mg daily for 6 months
Number of subjects: 262
Study: 25203576

Group type: EXPERIMENTAL
Intervention: High-pitch ultra-low-dose CT
Number of subjects: 60
Study: 22642357

Group type: EXPERIMENTAL
Intervention: Tonic contraction of lower half of the face
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tonic contraction of upper half of the face
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both upper and lower half manipulations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutral lower half-face combined with emotional expression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutral upper half-face combined with emotional expression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both upper and lower half manipulations with neutral faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both manipulations
Number of subjects: 0
Study: 20549168

Group type: EXPERIMENTAL
Intervention: Ottobock B500
Number of subjects: 12
Study: 19020244

Group type: EXPERIMENTAL
Intervention: Lower injection rate protocol: 20 mL of gadopentetate dimeglumine at 2 mL/s, 8 mL of gadopentetate dimeglumine at 1 mL/s, and 20 mL of saline solution at 1 mL/s.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Higher injection rate protocol: 20 mL of gadopentetate dimeglumine at 1.2 mL/s, 8 mL of gadopentetate dimeglumine at 0.7 mL/s, and 20 mL of saline solution at 0.7 mL/s.
Number of subjects: 80
Study: 16392777

Group type: EXPERIMENTAL
Intervention: Three-day treatment with trimethoprim
Number of subjects: 100

Group type: COMPARATOR
Intervention: Five-day treatment with trimethoprim
Number of subjects: 100
Study: 12190747

Group type: EXPERIMENTAL
Intervention: Doppler guided fluid optimisation (Group D)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 57
Study: 10648340

Group type: EXPERIMENTAL
Intervention: Combined-frequency jet ventilation (10 min, 15 and 600 breaths/min, inspiration/expiration time ratio = 1, driving pressure 750-1500 mm Hg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Monofrequent jet ventilation (low-frequency group: 15 breaths/min; high-frequency group: 600 breaths/min, 20 min)
Number of subjects: 23
Study: 8676600

Group type: EXPERIMENTAL
Intervention: 300 micrograms iodine per day (group A)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 100 micrograms iodine plus 100 micrograms levothyroxine per day (group B)
Number of subjects: 106
Study: 1534424

Group type: EXPERIMENTAL
Intervention: Dacron
Number of subjects: 165

Group type: COMPARATOR
Intervention: ePTFE
Number of subjects: 165
Study: 3931596

Group type: EXPERIMENTAL
Intervention: Mannitol added to potassium crystalloid solution
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 5% Albumin added to potassium crystalloid solution
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard potassium crystalloid solution
Number of subjects: 58
Study: 31103533

Group type: EXPERIMENTAL
Intervention: IMPACT (problem-solving + education intervention)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 607
Study: 29635610

Group type: EXPERIMENTAL
Intervention: In-person mindfulness training (IP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Virtual world mindfulness training (VW)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindfulness Training (combined IP and VW)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study: 27314118

Group type: COMPARATOR
Intervention: External connection (EC) implants
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Internal connection (IC) implants
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both EC and IC implants
Number of subjects: 120
Study: 23399677

Group type: COMPARATOR
Intervention: NerBloc® (rimabotulinumtoxinB) 2,500 U
Number of subjects: 0

Group type: COMPARATOR
Intervention: NerBloc® (rimabotulinumtoxinB) 5,000 U
Number of subjects: 0

Group type: COMPARATOR
Intervention: NerBloc® (rimabotulinumtoxinB) 10,000 U
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22254516

Group type: EXPERIMENTAL
Intervention: Magnetic stimulation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 64
Study: 19246708

Group type: EXPERIMENTAL
Intervention: Prism Adaptation (PA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Neutral Pointing (NP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prism Adaptation (PA) after NP treatment
Number of subjects: 20
Study: 17101300

Group type: EXPERIMENTAL
Intervention: Curcumin (1g after breakfast and 1g after evening meal) plus sulfasalazine or mesalamine
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo plus sulfasalazine or mesalamine
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 14727272

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% with a basal rate of 8 mL/h and a 2 mL patient-controlled bolus available each hour (8/2 group, n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ropivacaine 0.2% with a basal rate of 4 mL/h and a 6 mL patient-controlled bolus available each hour (4/6 group, n = 12)
Number of subjects: 24
Study: 11710756

Group type: EXPERIMENTAL
Intervention: Normotensive offspring of hypertensive parents
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 36
Study: 9136839

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA, 750 mg/day)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 7957433

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory monitoring (CRM)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Nonmonitoring
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (no history of cot death)
Number of subjects: 93
Study: 3066517

Group type: EXPERIMENTAL
Intervention: piperacillin + amikacin
Number of subjects: 76

Group type: COMPARATOR
Intervention: ceftazidime + amikacin
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: piperacillin
Number of subjects: 76

Group type: COMPARATOR
Intervention: ceftazidime
Number of subjects: 76
Study: 31619357

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 278

Group type: COMPARATOR
Intervention: Aflibercept 2.0 mg
Number of subjects: 278
Study: 29934295

Group type: EXPERIMENTAL
Intervention: Single postdischarge nurse‐led home visit
Number of subjects: 1500

Group type: COMPARATOR
Intervention: No visit (Control)
Number of subjects: 1500
Study: 27568806

Group type: EXPERIMENTAL
Intervention: Narcolepsy type 1 patients
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy matched controls
Number of subjects: 24

Group type: COMPARATOR
Intervention: Idiopathic hypersomnia patients
Number of subjects: 24
Study: 25393287

Group type: EXPERIMENTAL
Intervention: 50 mg zinc sulphate daily for three months
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: In vitro zinc sulphate
Number of subjects: 72
Study: 23559084

Group type: EXPERIMENTAL
Intervention: Cushing's syndrome (CS) patients
Number of subjects: 15
Study: 20675620

Group type: EXPERIMENTAL
Intervention: Testosterone supplementation (100 mg intramuscular every 2 weeks for 26 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone supplementation
Number of subjects: 0
Study: 19610505

Group type: EXPERIMENTAL
Intervention: 25G Quincke spinal needle
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 27G Quincke spinal needle
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 27G Whitacre spinal needle
Number of subjects: 480
Study: 19679505

Group type: EXPERIMENTAL
Intervention: Eccentric-only exercise protocol (ECC: 5 sets of 20 contractions)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Concentric-eccentric protocol (CON-ECC: 5 sets of 10 eccentric/10 concentric contractions)
Number of subjects: 13
Study: 16269634

Group type: EXPERIMENTAL
Intervention: AcPAO
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: SMO
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Acrolein
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Total polyamine oxidase (AcPAO + SMO)
Number of subjects: 19

Group type: COMPARATOR
Intervention: MRI/CT confirmation
Number of subjects: 19

Group type: COMPARATOR
Intervention: MRI confirmation in normal subjects
Number of subjects: 19
Study: 12102473

Group type: EXPERIMENTAL
Intervention: Combination therapy with cyclosporine (CSA) and methotrexate (MTX) plus prednisone (PDN) (group B)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Methotrexate (MTX) and prednisone (PDN) (group A)
Number of subjects: 24
Study: 9587881

Group type: EXPERIMENTAL
Intervention: Structured diet combined with exercise and behavior therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard dietary and behavioral treatments
Number of subjects: 0
Study: 7527453

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (CBV regimen: cyclophosphamide, carmustine, etoposide)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Sequential chemotherapy (ifosfamide, etoposide, asparaginase, cytarabine)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (CBV regimen)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Sequential chemotherapy
Number of subjects: 464
Study: 2737235

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.5 mg s.c. followed by metoclopramide 10 mg i.v.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Metoclopramide 10 mg i.v.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.5 mg s.c.
Number of subjects: 6
Study: 11959638

Group type: EXPERIMENTAL
Intervention: 60% maximal inspiratory pressure (MIP) during the fatigue trial
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (0% MIP, no diaphragm fatigue)
Number of subjects: 6
Study: 30231037

Group type: EXPERIMENTAL
Intervention: Compression-only CPR
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bag-valve-mask ventilation
Number of subjects: 18
Study: 27203508

Group type: EXPERIMENTAL
Intervention: Combination therapy (fluticasone furoate 100 μg and vilanterol 25 μg)
Number of subjects: 16485

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (100 μg)
Number of subjects: 16485

Group type: EXPERIMENTAL
Intervention: Vilanterol (25 μg)
Number of subjects: 16485

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 16485
Study: 25229902

Group type: EXPERIMENTAL
Intervention: Education intervention (4 sessions of 45-65 minutes with lectures, Q&A, educational booklets, and posters)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no education intervention)
Number of subjects: 80
Study: 22406878

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 21718

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21718
Study: 20363839

Group type: EXPERIMENTAL
Intervention: Aerobic training (educational program plus breathing exercises plus aerobic training)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (educational program plus breathing exercises)
Number of subjects: 101
Study: 17485195

Group type: EXPERIMENTAL
Intervention: SPEech Pathology Intervention Program for CHronic Cough (SPEICH‐C)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Healthy Lifestyle Education intervention program (HLE control)
Number of subjects: 82
Study: 15820588

Group type: EXPERIMENTAL
Intervention: Involvement in voluntary associations
Number of subjects: 1504

Group type: EXPERIMENTAL
Intervention: Neighbourhood of residence
Number of subjects: 1504
Study: 12581974

Group type: EXPERIMENTAL
Intervention: Glucocorticoid (20 mg/d for 10 d, gradually decreased afterwards) + vitamin B + coenzyme Q10
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vitamin B + coenzyme Q10
Number of subjects: 20
Study: 10088566

Group type: EXPERIMENTAL
Intervention: Expandable metallic Z stent (group A)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Repeated external-internal stent placement (group B)
Number of subjects: 18
Study: 8719584

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray
Number of subjects: 129

Group type: COMPARATOR
Intervention: Cetirizine
Number of subjects: 129
Study: 2327531

Group type: EXPERIMENTAL
Intervention: Laboratory method
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Freedom from Smoking
Number of subjects: 1041

Group type: COMPARATOR
Intervention: FreshStart
Number of subjects: 1041
Study: 7000474

Group type: EXPERIMENTAL
Intervention: Cimetidine (1200 mg daily)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 30626222

Group type: EXPERIMENTAL
Intervention: Partial sleep-deprivation (SD)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Partial sleep-deprivation with nap (SDN)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal (N)
Number of subjects: 15
Study: 29510715

Group type: EXPERIMENTAL
Intervention: Stand More AT Work (SMArT Work) intervention including strategies like height adjustable desks, senior management support, seminars, and face-to-face coaching sessions
Number of subjects: 70
Study: 27131288

Group type: EXPERIMENTAL
Intervention: Health Education Session (HES)
Number of subjects: 0
Study: 24582567

Group type: EXPERIMENTAL
Intervention: 3000 mg resveratrol daily for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 22205536

Group type: EXPERIMENTAL
Intervention: TissuGlu® surgical adhesive
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no TissuGlu application)
Number of subjects: 20
Study: 20089104

Group type: EXPERIMENTAL
Intervention: FCH PETCT imaging at 15 min after injection
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: FCH PETCT imaging at 60 min after injection
Number of subjects: 25
Study: 18059587

Group type: EXPERIMENTAL
Intervention: Whey protein plus carbohydrate beverage (10 g protein and 21 g fructose)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Carbohydrate-only beverage (21 g fructose and 10 g maltodextran)
Number of subjects: 8